UBA52 and colorectal carcinoma: GAS5 can inhibit CRC progression in vitro and in vivo by directly interacting with the WW structural domain of YAP, facilitating translocation of endogenous YAP from the nucleus to the cytoplasm, and promoting phosphorylation and subsequent ubiquitin-mediated degradation of YAP (85).